मूलभूत आँकड़े
| CIK | 93314 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to VolitionRx Limited
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLI |
|
| August 15, 2025 |
EXHIBIT 10.2 VolitionRx Limited Common Stock (par value $0.001 per share) Amendment No. 1 to Capital on Demand™ Sales Agreement August 14, 2025 JonesTrading Institutional Services LLC 325 Hudson Street, 6th Floor New York, NY 10013 Ladies and Gentlemen: Reference is made to that certain Capital on DemandTM Sales Agreement (the “Sales Agreement”), dated April 22, 2025, between VolitionRx Limited, a |
|
| August 14, 2025 |
EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 14, 2025 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exac |
|
| August 14, 2025 |
Up to $30,000,000 VOLITIONRX LIMITED Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-283088 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2025 and Prospectus Supplement dated April 22, 2025) Up to $30,000,000 VOLITIONRX LIMITED Common Stock This prospectus supplement amends and supplements certain information in the prospectus supplement dated April 22, 2025 (the “ATM Prospectus Supplement”), and the accompanying base pr |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incor |
|
| August 4, 2025 |
EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT VOLITIONRX LIMITED Warrant Shares: [] Exercise Date: August 5, 2025 Issuance Date: August 5, 2025 THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after Au |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2025 |
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering EXHIBIT 99.1 VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering HENDERSON, Nev., August 4, 2025/PRNewswire/—VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i) 156,250 shares of its common stock to certain directors and execu |
|
| August 4, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 1, 2025, by and between VolitionRx Limited, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS A. The Company and each Purchaser |
|
| August 4, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-283088 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2025) VOLITIONRX LIMITED 1,890,625 Shares of Common Stock Warrants to Purchase up to 1,734,375 Shares of Common Stock Up to 1,734,375 Shares of Common Stock Issuable Upon Exercise of the Warrants Pursuant to this prospectus supplement and the accompanying base prospectus, we are offeri |
|
| July 10, 2025 |
VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 July 10, 2025 VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 July 10, 2025 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 3, 2025 |
EXHIBIT 4.2 DESCRIPTION OF CAPITAL STOCK The following is a summary of all material characteristics of the capital stock of VolitionRx Limited, as set forth in our Second Amended and Restated Certificate of Incorporation, or our Charter, and our Amended and Restated Bylaws, or our Bylaws. References to “we,” “us,” and “our” refer to VolitionRx Limited. This summary does not purport to be complete |
|
| July 3, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) VolitionRx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fee Proposed Calculation Maximum Maximum or Carry Offering Aggregate Amount of Security Security Forward Amount Price Per Offering Registration Type Class Title Rule Registered(1) Unit(2) Price Fee Rate Fee Securities to Be Registered Fees to Be Paid Equity Common Stock, par value $0. |
|
| July 3, 2025 |
EXHIBIT 4.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of May 15, 2025, by and between VolitionRx Limited, a Delaware corporation (the “Company”), and Lind Global Asset Management XII LLC, a Delaware limited liability company (the “Investor”). BACKGROUND A. The board of |
|
| July 3, 2025 |
Second Amended and Restated Certificate of Incorporation, as amended and currently in effect. EXHIBIT 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOLITIONRX LIMITED VolitionRx Limited, a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: 1. The original Certificate of Incorporation was filed with the Secretary of State on September 24, 1998, under the name Standard Capital Corporation, |
|
| July 3, 2025 |
As filed with the Securities and Exchange Commission on July 3, 2025 As filed with the Securities and Exchange Commission on July 3, 2025 Registration No. |
|
| June 20, 2025 |
Certificate of Second Amendment of the Second Amended and Restated Certificate of Incorporation. EXHIBIT 3.1 CERTIFICATE OF SECOND AMENDMENT OF THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOLITIONRX LIMITED, a Delaware corporation VolitionRx Limited, a Delaware corporation (the “Corporation”), organized and existing under and by virtue of the Delaware General Corporation Law (the “DGCL”), does hereby certify that: FIRST: The original Certificate of Incorporation of the Cor |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Employ |
|
| May 15, 2025 |
EXHIBIT 10.3 THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILAB |
|
| May 15, 2025 |
EXHIBIT 10.8 GUARANTOR SECURITY AGREEMENT This GUARANTOR SECURITY AGREEMENT (this “Agreement”), dated as of May 15, 2025, is by and among Singapore Volition Pte. Limited, a corporation organized under the laws of Singapore (“Volition Singapore”), Volition Global Services SRL, a corporation organized under the laws of Belgium (“Volition Global”), Volition Diagnostics UK Limited, a corporation organ |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exa |
|
| May 15, 2025 |
EXHIBIT 10.11 PLEDGE AGREEMENT This Pledge Agreement (this “Agreement”) is entered into as of May 15, 2025, by and between Singapore Volition Pte. Limited, a corporation organized under the laws of Singapore (the “Company”), and Lind Global Asset Management XII LLC, a Delaware limited liability company (the “Secured Party”). WHEREAS, VolitionRx Limited, a Delaware corporation (the “Borrower”) is t |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorpor |
|
| May 15, 2025 |
EXHIBIT 10.5 SECURITY AGREEMENT This SECURITY AGREEMENT (this “Agreement”), dated as of May 15, 2025, is by and between VolitionRx Limited, a Delaware corporation (the “Company”) and Lind Global Asset Management XII LLC, a Delaware limited liability company (the “Secured Party”). WHEREAS, the Company (a) and the Secured Party have entered into that certain Securities Purchase Agreement dated as of |
|
| May 15, 2025 |
EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of May 15, 2025, by and between VolitionRx Limited, a Delaware corporation (the “Company”), and Lind Global Asset Management XII LLC, a Delaware limited liability company (the “Investor”). BACKGROUND A. The board o |
|
| May 15, 2025 |
EXHIBIT 10.7 PLEDGE AGREEMENT This Pledge Agreement (this “Agreement”) is entered into as of May 15, 2025, by and between VolitionRx Limited, a Delaware corporation (the “Company”), and Lind Global Asset Management XII LLC, a Delaware limited liability company (the “Secured Party”). WHEREAS, the Company and the Secured Party have entered into that certain Securities Purchase Agreement dated as of |
|
| May 15, 2025 |
EXHIBIT 10.4 THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAI |
|
| May 15, 2025 |
EXHIBIT 99.1 VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, May 15, 2025 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a |
|
| May 15, 2025 |
EXHIBIT 10.6 GUARANTY GUARANTY (the “Guaranty”), dated as of May 15, 2025, by Singapore Volition Pte. Limited, a corporation organized under the laws of Singapore (“Volition Singapore”), Volition Global Services SRL, a corporation organized under the laws of Belgium (“Volition Global”), Belgian Volition SRL, a corporation organized under the laws of Belgium (“Volition Belgium”), Volition Diagnosti |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 25, 2025 |
VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 April 25, 2025 VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 April 25, 2025 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 22, 2025 |
Up to $7,500,000 VOLITIONRX LIMITED Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-283088 PROSPECTUS SUPPLEMENT (To Prospectus dated April 18, 2025) Up to $7,500,000 VOLITIONRX LIMITED Common Stock We have entered into a Capital on Demand™ Sales Agreement, dated April 22, 2025, or the Sales Agreement, with JonesTrading Institutional Services LLC, or Jones, relating to the issuance and sale of our common stock offered by this |
|
| April 22, 2025 |
EXHIBIT 1.1 VolitionRx Limited Common Stock (par value $0.001 per share) Capital on Demand™ Sales Agreement April 22, 2025 JonesTrading Institutional Services LLC 325 Hudson Street., 6th Floor New York, NY 10013 Ladies and Gentlemen: VolitionRx Limited, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as f |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorp |
|
| April 16, 2025 |
VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 April 16, 2025 VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 April 16, 2025 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 16, 2025 |
VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 April 16, 2025 VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 April 16, 2025 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 11, 2025 |
VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 April 11, 2025 VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 April 11, 2025 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 11, 2025 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) VolitionRx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common stock, par value $0. |
|
| April 11, 2025 |
As Filed with the Securities and Exchange Commission on April 11, 2025 As Filed with the Securities and Exchange Commission on April 11, 2025 Registration No. |
|
| April 4, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) VOLITIONRX LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Securities to Be Registered Fees to Be Paid Equity Common stock, par value $0. |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorpo |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact na |
|
| March 31, 2025 |
EXHIBIT 10.43 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, OR (II) CONTAINS PERSONALLY IDENTIFIABLE INFORMATION, OMITTED PURSUANT TO ITEM 601(A)(6) UNDER REGULATION S-K. INDEPENDENT DIRECTOR AGREEMENT This INDEPENDENT DIRECTOR AGREEMENT is dated November 6, 202 |
|
| March 31, 2025 |
Insider Trading & Blackout Policy. EXHIBIT 19.1 Insider Trading & Blackout Policy Document No: HR-01-05-02 (a) Revision: English Language Version Document Type: Policy Owner: Corporate Secretary Review Due Date: May 2025 Approvals - On File 1. Background and Purpose 1.1 VolitionRx Limited (the “Company”) is adopting this amended and restated Insider Trading & Blackout Policy (this “Policy”) as of April 24, 2023, in light of federal |
|
| March 31, 2025 |
EXHIBIT 99.1 VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time Henderson, Nevada, March 31, 2025 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results |
|
| March 31, 2025 |
EXHIBIT 21.1 SUBSIDIARIES OF VOLITIONRX LIMITED Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Singapore Volition Pte. Limited (100% subsidiary of VolitionRx Limited) Singapore Belgian Volition SRL (100% subsidiary of Singapore Volition Pte. Limited) Belgium Volition Diagnostics UK Limited (100% subsidiary of Belgian Volition SRL) United Kingdom Volition America, I |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorp |
|
| March 26, 2025 |
EXHIBIT 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 24, 2025, by and between VolitionRx Limited, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS A. The Company |
|
| March 26, 2025 |
EXHIBIT 99.1 VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev., March 26, 2025/PRNewswire/—VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics |
|
| March 26, 2025 |
Form of Investor Common Stock Purchase Warrant EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT VOLITIONRX LIMITED Warrant Shares: [] Exercise Date: March 26, 2025 Issuance Date: March 26, 2025 THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after Ma |
|
| March 26, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of incorporation) (Commission File |
|
| March 26, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-259783 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2021) VOLITIONRX LIMITED 4,102,723 Shares of Common Stock Warrants to Purchase up to 1,739,087 Shares of Common Stock Up to 1,739,087 Shares of Common Stock Issuable Upon Exercise of the Warrants Pursuant to this prospectus supplement and the accompanying base prospectus, we are offe |
|
| December 9, 2024 |
Form of Form A Common Stock Purchase Warrant. EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT VOLITIONRX LIMITED Warrant Shares: [] Exercise Date: December 9, 2024 Issuance Date: December 9, 2024 THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| December 9, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 9, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-259783 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2021) VOLITIONRX LIMITED 3,303,037 Shares of Common Stock Warrants to Purchase up to 4,286,082 Shares of Common Stock Up to 4,286,082 Shares of Common Stock Issuable Upon Exercise of the Warrants Pursuant to this prospectus supplement and the accompanying base prospectus, we are offe |
|
| December 9, 2024 |
EXHIBIT 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 5, 2024, by and between VolitionRx Limited, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS A. The Compan |
|
| December 9, 2024 |
EXHIBIT 99.1 VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev., Dec. 6, 2024/PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics |
|
| December 9, 2024 |
Form of Form B Common Stock Purchase Warrant. EXHIBIT 4.2 COMMON STOCK PURCHASE WARRANT VOLITIONRX LIMITED Warrant Shares: [] Exercise Date: December 9, 2024 Issuance Date: December 9, 2024 THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| November 14, 2024 |
EXHIBIT 99.1 VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, November 14, 2024 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial resu |
|
| November 14, 2024 |
VNRX / VolitionRx Limited / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-vnrx093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VOLITIONRX LTD (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 928661107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Inc |
|
| November 14, 2024 |
EXHIBIT 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, OR (II) CONTAINS PERSONALLY IDENTIFIABLE INFORMATION, OMITTED PURSUANT TO ITEM 601(A)(6) UNDER REGULATION S-K. Permanent employment contract Between Belgian Volition SRL, 22 Rue Phocas Lejeune, 5032 Isne |
|
| November 14, 2024 |
VNRX / VolitionRx Limited / Lagoda Investment Management, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VolitionRX Limited (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED |
|
| November 14, 2024 |
EXHIBIT 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, OR (II) CONTAINS PERSONALLY IDENTIFIABLE INFORMATION, OMITTED PURSUANT TO ITEM 601(A)(6) UNDER REGULATION S-K. FIRST AMENDMENT TO CONSULTING SERVICES AGREEMENT This FIRST AMENDMENT, effective as of 1 Sep |
|
| November 8, 2024 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) VolitionRx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common stock, par value $0. |
|
| November 8, 2024 |
As Filed with the Securities and Exchange Commission on November 8, 2024 As Filed with the Securities and Exchange Commission on November 8, 2024 Registration No. |
|
| November 6, 2024 |
Volition Appoints Timothy I. Still as Chairman EXHIBIT 99.1 Volition Appoints Timothy I. Still as Chairman Henderson, Nevada, November 06, 2024 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with RE |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission Fil |
|
| September 30, 2024 |
Volition Appoints Dr. Ethel Rubin as an Independent Director EXHIBIT 99.1 Volition Appoints Dr. Ethel Rubin as an Independent Director Henderson, Nevada, September 30, 2024 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Commit |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS E |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS E |
|
| September 16, 2024 |
EXHIBIT 99.1 2 |
|
| September 16, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS E |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VolitionRx Limited (Exac |
|
| August 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission File |
|
| August 14, 2024 |
EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 14, 2024 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announced financial resul |
|
| August 12, 2024 |
Form of Series B Common Stock Warrant. EXHIBIT 4.3 SERIES B COMMON STOCK PURCHASE WARRANT VOLITIONRX LIMITED Warrant Shares: Initial Exercise Date: February 12, 2025 Issuance Date: August 12, 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| August 12, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of incorporation) (Commission File |
|
| August 12, 2024 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 8, 2024, between VolitionRx Limited, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| August 12, 2024 |
EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT VOLITIONRX LIMITED Warrant Shares Initial Exercise Date: August 12, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “In |
|
| August 12, 2024 |
Form of Series A Common Stock Warrant. EXHIBIT 4.2 SERIES A COMMON STOCK PURCHASE WARRANT VOLITIONRX LIMITED Warrant Shares: Initial Exercise Date: February 12, 2025 Issuance Date: August 12, 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| August 12, 2024 |
EXHIBIT 99.1 VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering $7 million upfront with up to an additional $14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HENDERSON, Nev., Aug. 9, 2024/PRNewswire/—VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics company, annou |
|
| August 12, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-259783 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2021) VOLITIONRX LIMITED Up to 9,170,000 Shares of Common Stock Up to 3,557,273 Pre-Funded Warrants to Purchase up to 3,557,273 Shares of Common Stock Up to 12,727,273 Series A Common Stock Purchase Warrants to Purchase up to 12,727,273 Shares of Common Stock Up to 12,727,273 Series |
|
| July 24, 2024 |
EXHIBIT 99.1(d) NOTICE OF RESTRICTED STOCK UNIT AWARD VOLITIONRX LIMITED 2024 STOCK INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2024 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Restricted Stock Unit Award (the “Notice”) and the attached Restricted Stock Unit Agreement (the “RSU Agreement”). You hav |
|
| July 24, 2024 |
As filed with the Securities and Exchange Commission on July 24, 2024 As filed with the Securities and Exchange Commission on July 24, 2024 Registration No. |
|
| July 24, 2024 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) VolitionRx Limited (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| July 24, 2024 |
EXHIBIT 99.1(f) NOTICE OF STOCK BONUS AWARD VOLITIONRX LIMITED 2024 STOCK INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2024 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Stock Bonus Award (the “Notice”) and the attached Stock Bonus Award Agreement (the “Stock Bonus Agreement”). You have been granted a |
|
| July 24, 2024 |
EXHIBIT 99.1(c) NOTICE OF RESTRICTED STOCK AWARD VOLITIONRX LIMITED 2024 STOCK INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2024 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Restricted Stock Award (the “Notice”) and the attached Restricted Stock Agreement (the “Restricted Stock Agreement”). You have |
|
| July 24, 2024 |
Form of Notice of Stock Option Grant and Stock Option Agreement under the 2024 Stock Incentive Plan. EXHIBIT 99.1(a) NOTICE OF STOCK OPTION GRANT VOLITIONRX LIMITED 2024 STOCK INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2024 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Stock Option Grant (the “Notice of Grant”) and the attached Stock Option Agreement (the “Option Agreement”). You have been granted |
|
| July 24, 2024 |
Second Amended and Restated Certificate of Incorporation, as amended and currently in effect. EXHIBIT 4.2 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOLITIONRX LIMITED VolitionRx Limited, a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: 1. The original Certificate of Incorporation was filed with the Secretary of State on September 24, 1998, under the name Standard Capital Corporation, |
|
| July 24, 2024 |
EXHIBIT 99.1(e) NOTICE OF STOCK APPRECIATION RIGHT AWARD VOLITIONRX LIMITED 2024 STOCK INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2024 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Stock Appreciation Right Award (the “Notice of Grant”) and the attached Stock Appreciation Right Agreement (the “SAR Ag |
|
| July 24, 2024 |
EXHIBIT 99.1(b) NOTICE OF PERFORMANCE SHARES AWARD VOLITIONRX LIMITED 2024 STOCK INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the VolitionRx Limited (the “Company”) 2024 Stock Incentive Plan (the “Plan”) shall have the same meanings in this Notice of Performance Shares Award (the “Notice”) and the attached Performance Shares Award Agreement (the “Performance Shares Agreemen |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorpor |
|
| July 3, 2024 |
Certificate of Amendment of Second Amended and Restated Certificate of Incorporation. EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOLITIONRX LIMITED, a Delaware corporation VolitionRx Limited, a Delaware corporation, organized and existing under and by virtue of the Delaware General Corporation Law (the “DGCL”), does hereby certify that: FIRST: The original Certificate of Incorporation of the Corporation was filed with the off |
|
| July 3, 2024 |
EXHIBIT 10.1 VOLITIONRX LIMITED 2024 STOCK INCENTIVE PLAN As adopted by the Board of Directors on April 24, 2024 ARTICLE 1 PURPOSES OF THE PLAN 1.1 Purposes. The purposes of the Plan are (a) to enhance the Company’s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successf |
|
| June 27, 2024 |
2024 Mid-Year Review with Cameron Reynolds, Group CEO of Volition EXHIBIT 99.2 2024 Mid-Year Review with Cameron Reynolds, Group CEO of Volition Ahead of Volition’s Annual Meeting of Stockholders next week, I am delighted to share our key highlights from the first half of 2024 and provide a preview of upcoming milestones. Thank you to you all for your continued support in helping us to advance our mission to save the lives and improve outcomes of millions of peo |
|
| June 27, 2024 |
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting EXHIBIT 99.1 VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting Henderson, Nevada, June 27, 2024 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024. Volition’s mid-year review encompasses key highlights inc |
|
| June 27, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission File N |
|
| June 25, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280217 PROSPECTUS 73,263 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 73,263 shares of common stock, par value $0.001 per share, of VolitionRx Limited (the “Company,” “we,” “us,” or “our”), by the selling stockholder named in this prospectus or any post-effective amendment to the registration |
|
| June 21, 2024 |
VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 June 21, 2024 VOLITIONRX LIMITED 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 June 21, 2024 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 14, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) VolitionRx Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fee Proposed Calculation Maximum Maximum or Carry Offering Aggregate Amount of Security Security Forward Amount Price Per Offering Registration Type Class Title Rule Registered(1) Unit(2) Price(2) Fee Rate Fee Securities to Be Registered Fees to Be Paid Equity Common Stock, par value $0. |
|
| June 14, 2024 |
As filed with the Securities and Exchange Commission on June 14, 2024 As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 13, 2024 |
Amended and Restated Bylaws, as amended and currently in effect. EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF VOLITIONRX LIMITED TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 1.3 Books and Records 1 ARTICLE II - MEETINGS OF STOCKH 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance Notice Procedures 2 2.5 Notice of Stockholders’ Meetings 7 2.6 Quorum 7 2.7 Adjourned Meeting; Notice |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VolitionRx Limited (Exa |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| May 13, 2024 |
EXHIBIT 99.1 VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, May 13, 2024 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announced financial results and a |
|
| April 26, 2024 |
CERTIFICATE OF AMENDMENT THE AMENDED AND RESTATED BYLAWS VOLITIONRX LIMITED a Delaware corporation EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED BYLAWS OF VOLITIONRX LIMITED a Delaware corporation The undersigned hereby certifies that he is the duly elected, qualified and acting Corporate Secretary of VolitionRx Limited, a Delaware corporation (the “Corporation”), and that the Amended and Restated Bylaws of the Corporation were amended by resolution of the Board of Directors |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2024 VolitionRx Limited (Exact Name of the Registrant as Specified in Charter) Delaware 001-36833 91-1949078 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact na |
|
| March 25, 2024 |
Clawback and Forfeiture Policy EXHIBIT 97.1 VOLITIONRX LIMITED CLAWBACK AND FORFEITURE POLICY The Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) has adopted this Clawback and Forfeiture Policy (this “Policy”) to comply with Section 10D and Rule 10D-1 of the Exchange Act, and to establish the circumstances under which the Company shall seek recoupment and forfeiture of Incentive-Based Compensation Receive |
|
| March 25, 2024 |
EXHIBIT 10.36 Dated: March 19, 2024 Contract of Employment between Volition Diagnostics UK Ltd and Dr Andrew Retter 1. Introduction This document is the contract of employment (“Agreement”) between you: Dr Andrew Retter of [***] the “Employee” and: Volition Diagnostics UK Ltd, a company registered in England and Wales with a Company Number of 09871726 of with its offices located at 93-95 Glouceste |
|
| March 25, 2024 |
EXHIBIT 99.1 VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, March 25, 2024 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announced financial result |
|
| March 25, 2024 |
EXHIBIT 21.1 SUBSIDIARIES OF VOLITIONRX LIMITED Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Singapore Volition Pte. Limited (100% subsidiary of VolitionRx Limited) Singapore Belgian Volition SRL (100% subsidiary of Singapore Volition Pte. Limited) Belgium Volition Diagnostics UK Limited (100% subsidiary of Belgian Volition SRL) United Kingdom Volition America, I |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission File |
|
| March 19, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 19, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorp |
|
| March 19, 2024 |
Volition appoints Dr Andrew Retter as Chief Medical Officer EXHIBIT 99.1 Volition appoints Dr Andrew Retter as Chief Medical Officer Henderson, Nevada, March 19, 2024 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024. Dr Retter will provide medical leadership at Volition and ensure the company’s scientific and clini |
|
| February 14, 2024 |
VNRX / VolitionRx Limited / Lagoda Investment Management, L.P. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* VolitionRX Limited (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 9, 2024 |
VNRX / VolitionRx Limited / Reynolds Cameron John - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* VolitionRx Limited (Name of Company) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) Cameron Reynolds 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 +1 (646) 650-1351 With a copy to: Marc |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2023 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| December 20, 2023 |
VolitionRx Limited December 20, 2023 VolitionRx Limited December 20, 2023 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 5, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Emp |
|
| December 5, 2023 |
EXHIBIT 99.1 VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre Henderson, Nevada, December 5, 2023 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A. (“WE”) i |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2023 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED |
|
| November 14, 2023 |
EXHIBIT 99.1 VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Wednesday, November 15, at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, November 14, 2023 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the t |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exac |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incor |
|
| August 14, 2023 |
EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 14, 2023 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the second |
|
| July 14, 2023 |
As filed with the Securities and Exchange Commission on July 14, 2023 As filed with the Securities and Exchange Commission on July 14, 2023 Registration No. |
|
| July 14, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) VolitionRx Limited (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Title of Each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(3) Equity Common Stock, par value $0. |
|
| June 30, 2023 |
2015 Stock Incentive Plan, as amended. EXHIBIT 10.1 VOLITIONRX LIMITED 2015 STOCK INCENTIVE PLAN As amended April 17, 2023 ARTICLE 1 PURPOSES OF THE PLAN 1.1 Purposes. The purposes of the Plan are (a) to enhance the Company’s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2023 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Employ |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| June 5, 2023 |
EXHIBIT 1.1 Execution Version VOLITIONRX LIMITED 13,000,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement June 1, 2023 Prime Executions, Inc. dba Freedom Capital Markets. As Representative of the several Underwriters listed in Schedule A hereto c/o Prime Executions, Inc. dba Freedom Capital Markets 40 Wall St, 58th Floor New York, NY 10005 Ladies and Gentlemen: Volitio |
|
| June 5, 2023 |
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock EXHIBIT 99.1 VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock HENDERSON, Nevada, May 31, 2023 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the und |
|
| June 5, 2023 |
Form of Underwriter Warrant issued to Prime Executions, Inc. dba Freedom Capital Markets. EXHIBIT 4.1 UNDERWRITER COMMON STOCK PURCHASE WARRANT VOLITIONRX LIMITED Warrant Shares: 390,000 Initial Exercise Date: December 4, 2023 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Prime Executions, Inc., doing business as Freedom Capital Markets, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exerc |
|
| June 5, 2023 |
VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock EXHIBIT 99.2 VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock HENDERSON, Nevada, June 1, 2023 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price |
|
| June 2, 2023 |
VOLITIONRX LIMITED 13,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-259783 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2021) VOLITIONRX LIMITED 13,000,000 Shares of Common Stock We are offering 13,000,000 shares of our common stock, par value $0.001 per share, at a price of $1.27 per share. Our common stock is listed on the NYSE American market, or the NYSE American, under the symbol “VNRX.” On May 3 |
|
| May 31, 2023 |
SUBJECT TO COMPLETION, DATED MAY 31, 2023 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2023 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| May 10, 2023 |
EXHIBIT 99.1 VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, May 10, 2023 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the first quarte |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exa |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2023 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Emplo |
|
| March 15, 2023 |
EXHIBIT 99.1 VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time · Executed global licensing and supply agreement with Heska Corporation (“Heska”) to distribute Nu.Q® Vet Cancer Test at the Point of Care with a $10 million upfront paymen |
|
| March 15, 2023 |
EXHIBIT 21.1 SUBSIDIARIES OF VOLITIONRX LIMITED Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Singapore Volition Pte. Limited (100% subsidiary of VolitionRx Limited) Singapore Belgian Volition SRL (100% subsidiary of Singapore Volition Pte. Limited) Belgium Volition Diagnostics UK Limited (100% subsidiary of Belgian Volition SRL) United Kingdom Volition America, I |
|
| March 15, 2023 |
EXHIBIT 10.27 SINGAPORE VOLITION PTE. LIMITED EMPLOYMENT AGREEMENT GROUP CHIEF EXECUTIVE OFFICER This Employment Agreement (“Agreement”) is dated March 13, 2023 (“Execution Date”) and is effective from March 01, 2023 (the “Effective Date”) by and between Singapore Volition Pte. Limited, a Singapore corporation (“Company” or “We”) and Cameron Reynolds (“Employee” or “You”). The Company and Employee |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact na |
|
| February 21, 2023 |
VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock EXHIBIT 99.2 VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock HENDERSON, Nevada, February 17, 2023 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 4,300,000 shares of its common stock at a public offering p |
|
| February 21, 2023 |
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock EXHIBIT 99.1 VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock HENDERSON, Nevada, February 16, 2023 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant th |
|
| February 21, 2023 |
EXHIBIT 1.1 4,300,000 SHARES OF COMMON STOCK VOLITIONRX LIMITED UNDERWRITING AGREEMENT February 17, 2023 Newbridge Securities Corporation 1200 N Federal Hwy, Suite 400 Boca Raton, Florida 33432 Ladies and Gentlemen: The undersigned, VolitionRx Limited, a company incorporated under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities d |
|
| February 21, 2023 |
4,300,000 Shares VOLITIONRX LIMITED Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-259783 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2021) 4,300,000 Shares VOLITIONRX LIMITED Common Stock We are offering 4,300,000 shares of our common stock, par value $0.001 per share, at a price of $1.75 per share. Our common stock is listed on the NYSE American Market under the symbol “VNRX.” On February 16, 2023, the last repor |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2023 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| February 16, 2023 |
SUBJECT TO COMPLETION, DATED FEBRUARY 16, 2023 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 14, 2023 |
VNRX / VolitionRX Ltd / Lagoda Investment Management, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* VolitionRX Limited (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Inc |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED |
|
| November 14, 2022 |
EXHIBIT 99.1 VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, November 15, at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, November 14, 2022 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (?Volition?) today announced financial results and a business update for the thi |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Inc |
|
| September 30, 2022 |
As filed with the Securities and Exchange Commission on September 30, 2022 As filed with the Securities and Exchange Commission on September 30, 2022 Registration No. |
|
| September 30, 2022 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) VolitionRx Limited (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Title of Each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered(1)(2) Proposed Maximum Offering Price Per Share(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(3) Equity Common Stock, par value $0. |
|
| August 16, 2022 |
Volition Appoints Mickie Henshall as an Independent Director EXHIBIT 99.1 Volition Appoints Mickie Henshall as an Independent Director Henderson, Nevada, August 16, 2022 /PRNewswire/ - VolitionRx Limited (NYSE: VNRX) (?Volition?), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to its board of directors effective August 15, 2022. Ms. Henshall was also appointed as a member of the Compensation Committee and the Nominati |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Empl |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission File |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exac |
|
| August 10, 2022 |
EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, August 11, at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 10, 2022 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (?Volition?) today announced financial results and a business update for the secon |
|
| August 2, 2022 |
EXHIBIT 1.1 3,000,000 SHARES OF COMMON STOCK VOLITIONRX LIMITED UNDERWRITING AGREEMENT July 29, 2022 Newbridge Securities Corporation 1200 N Federal Hwy, Suite 400 Boca Raton, Florida 33432 As the Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, VolitionRx Limited, a company incorporated under the laws of Delaware (collectively w |
|
| August 2, 2022 |
VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock EXHIBIT 99.2 VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock HENDERSON, Nevada, July 29, 2022 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Employ |
|
| August 2, 2022 |
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock EXHIBIT 99.1 VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock HENDERSON, Nevada, July 28, 2022 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Volition. In addi |
|
| August 2, 2022 |
VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock EX-99.3 6 vnrxex993.htm EXHIBIT 99.3 PRESS RELEASE EXHIBIT 99.3 VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common Stock HENDERSON, Nevada, August 2, 2022 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 3,450,00 |
|
| August 1, 2022 |
3,000,000 Shares VOLITIONRX LIMITED Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-259783 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2021) 3,000,000 Shares VOLITIONRX LIMITED Common Stock We are offering 3,000,000 shares of our common stock, par value $0.001 per share, at a price of $2.00 per share. Our common stock is listed on The NYSE American Market under the symbol “VNRX.” On July 27, 2022, the last reported |
|
| July 28, 2022 |
SUBJECT TO COMPLETION, DATED JULY 28, 2022 424B5 1 vnrx424b5.htm 424B5 PRELIMINARY PROSPECTUS The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Filed Pursuant to Rule 424(b)(5) Registration No. 333-2 |
|
| June 14, 2022 |
2015 Stock Incentive Plan, as amended EXHIBIT 10.1 VOLITIONRX LIMITED 2015 STOCK INCENTIVE PLAN As amended April 4, 2022 ARTICLE 1 PURPOSES OF THE PLAN 1.1 Purposes. The purposes of the Plan are (a) to enhance the Company?s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Employ |
|
| May 20, 2022 |
EX-1.1 2 vnrxex11.htm EXHIBIT 1.1 EQUITY DISTRIBUTION AGREEMENT EXHIBIT 1.1 VOLITIONRX LIMITED $25,000,000 COMMON STOCK EQUITY DISTRIBUTION AGREEMENT May 20, 2022 Jefferies LLC 520 Madison Avenue New York, NY 10022 Ladies and Gentlemen: VolitionRx Limited, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC (the “Agent”), as follows: 1. Issuance and |
|
| May 20, 2022 |
Up to $25,000,000 VOLITIONRX LIMITED Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-259783 PROSPECTUS SUPPLEMENT (To Prospectus dated November 8, 2021) Up to $25,000,000 VOLITIONRX LIMITED Common Stock We have entered into an Equity Distribution Agreement, dated May 20, 2022, or the Distribution Agreement, with Jefferies LLC, or Jefferies, relating to our common stock, par value $0.001 per share, offered by this prospectus sup |
|
| May 20, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| May 11, 2022 |
EXHIBIT 99.1 VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time AUSTIN, Texas, May 11, 2022 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (?Volition?) today announced financial results and a business update for the first quarter en |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exa |
|
| May 11, 2022 |
EXHIBIT 10.1 Certain confidential information contained in this document, marked by brackets as [***], has been omitted because it is not material and the registrant customarily and actually treats it as private or confidential. In addition, certain personal information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regu |
|
| April 28, 2022 |
DEF 14A 1 vnrxdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| March 30, 2022 |
EXHIBIT 21.1 SUBSIDIARIES OF VOLITIONRX LIMITED Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Singapore Volition Pte. Limited (100% subsidiary of VolitionRx Limited) Singapore Belgian Volition SRL (100% subsidiary of Singapore Volition Pte. Limited) Belgium Volition Diagnostics UK Limited (100% subsidiary of Belgian Volition SRL) United Kingdom Volition America, I |
|
| March 30, 2022 |
EXHIBIT 99.1 VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00 am U.S. Eastern Time ? Executed global licensing and supply agreement with Heska Corporation to distribute Nu.Q? Vet Cancer Screening Test at the Point of Care with a $10 million upfront payment |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact na |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Emplo |
|
| March 29, 2022 |
EXHIBIT 99.1 Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q? Vet Cancer Screening Test at the Point of Care AUSTIN, Texas, March 29, 2022 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (?Volition?), a multi-national epigenetics company, has announced the signing of an exclusive global supply and licensing agreement with Heska Co |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2022 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Emplo |
|
| February 14, 2022 |
VNRX / VolitionRX Ltd / Lagoda Investment Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VolitionRX Limited (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| November 10, 2021 |
EXHIBIT 10.1 VOLITION AMERICA, INC. EMPLOYMENT AGREEMENT CHIEF OPERATING OFFICER This Employment Agreement (?Agreement?) is effective on September 15, 2021 (the ?Effective Date?) by and between Volition America, Inc., a Delaware corporation with its office located at 13215 Bee Cave Parkway, Suite 125 Galleria Oaks B, Austin, Texas 78738 (?Company?) and Gaetan Michel (?Employee?). The Company and E |
|
| November 10, 2021 |
EXHIBIT 10.3 VOLITION DIAGNOSTICS UK LIMITED EMPLOYMENT AGREEMENT GROUP GENERAL COUNSEL This Employment Agreement (?Agreement?) is dated August 23, 2021 (?Execution Date?), by and between Volition Diagnostics UK Limited, incorporated and registered in England and Wales with company number 09871726, with its office located at 93-95 Gloucester Place, London, W1U 6JQ (?Company?) and Nick Plummer (?Em |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED |
|
| November 10, 2021 |
EXHIBIT 99.1 VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time ? Healthy balance sheet with approximately $22.9 million in cash and cash equivalents ? In advanced term sheet negotiations with three large multi-national veterinary compa |
|
| November 10, 2021 |
Certain confidential information contained in this document, marked by [***], has been omitted because it (i) is not material and would be competitively harmful if publicly disclosed, or (ii) contains personally identifiable information, omitted pursuant to Item 601(a)(6) under Regulation S-K. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2021 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Inc |
|
| November 4, 2021 |
As filed with the Securities and Exchange Commission on November 4, 2021 As filed with the Securities and Exchange Commission on November 4, 2021 Registration No. |
|
| November 4, 2021 |
VOLITIONRX LIMITED 13215 Bee Cave Parkway Suite 125, Galleria Oaks B Austin, Texas 78738 November 4, 2021 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 24, 2021 |
As filed with the Securities and Exchange Commission on September 24, 2021 As filed with the Securities and Exchange Commission on September 24, 2021 Registration No. |
|
| September 24, 2021 |
EXHIBIT 1.2 VOLITIONRX LIMITED $25,000,000 COMMON STOCK EQUITY DISTRIBUTION AGREEMENT September 24, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, New York 10004 Ladies and Gentlemen: VolitionRx Limited, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. and Opp |
|
| August 11, 2021 |
EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, August 12, at 8:00 a.m. U.S. Eastern Time ? Strong balance sheet with approximately $27.9 million in cash and cash equivalents ? Strengthened the Company?s veterinary leadership team to drive commercial focus ? Expa |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2021 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction of Incorporation) (Commission File |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exac |
|
| July 23, 2021 |
As filed with the Securities and Exchange Commission on July 23, 2021 As filed with the Securities and Exchange Commission on July 23, 2021 Registration No. |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2021 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Employ |
|
| June 22, 2021 |
2015 Stock Incentive Plan, as amended. VOLITIONRX LIMITED 2015 STOCK INCENTIVE PLAN As amended March 31, 2021 ARTICLE 1 PURPOSES OF THE PLAN 1. |
|
| May 11, 2021 |
Certain confidential information contained in this document, marked by [***], has been omitted because it (i) is not material and would be competitively harmful if publicly disclosed, or (ii) contains personally identifiable information, omitted pursuant to Item 601(a)(6) under Regulation S-K. |
|
| May 11, 2021 |
Certain confidential information contained in this document, marked by [***], has been omitted because it (i) is not material and would be competitively harmful if publicly disclosed, or (ii) contains personally identifiable information, omitted pursuant to Item 601(a)(6) under Regulation S-K. |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2021 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| May 11, 2021 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED |
|
| May 11, 2021 |
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Wednesday, May 12, at 8:00 a. |
|
| April 29, 2021 |
our Definitive Proxy Statement on Schedule 14A, as filed with the SEC on April 29, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2021 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Emplo |
|
| March 29, 2021 |
VolitionRx Limited Appoints Two New Directors VolitionRx Limited Appoints Two New Directors AUSTIN, Texas, March 29, 2021 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (?Volition?), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Ms. |
|
| March 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 22, 2021 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Emplo |
|
| March 22, 2021 |
Certain confidential information contained in this document, marked by [***], has been omitted because it (i) is not material and would be competitively harmful if publicly disclosed, or (ii) contains personally identifiable information, omitted pursuant to Item 601(a)(6) under Regulation S-K Exhibit 10. |
|
| March 22, 2021 |
Certain confidential information contained in this document, marked by [***], has been omitted because it (i) is not material and would be competitively harmful if publicly disclosed, or (ii) contains personally identifiable information, omitted pursuant to Item 601(a)(6) under Regulation S-K. |
|
| March 22, 2021 |
VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, March 23 at 8:00 a. |
|
| March 22, 2021 |
Common Stock Warrant issued by VolitionRx Limited to Gael Forterre, dated January 1, 2021. Certain confidential information contained in this document, marked by [***], has been omitted because it (i) is not material and would be competitively harmful if publicly disclosed, or (ii) contains personally identifiable information, omitted pursuant to Item 601(a)(6) under Regulation S-K. |
|
| March 22, 2021 |
Exhibit 10.20 VOLITION AMERICA, INC. EMPLOYMENT AGREEMENT GROUP CHIEF COMMERCIAL OFFICER This Agreement (?Agreement?) is entered into as of February 01, 2021 (the ?Effective Date?) by and between Volition America, Inc., a Delaware corporation (?Company?) and Gael Forterre (?Employee?). The Company and Employee are sometimes referred to herein individually as a ?Party? or collectively as the ?Parti |
|
| March 22, 2021 |
Exhibit 21.1 SUBSIDIARIES OF VOLITIONRX LIMITED Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Singapore Volition Pte. Limited (100% subsidiary of VolitionRx Limited) Singapore Belgian Volition SRL (99.9% subsidiary of Singapore Volition Pte. Limited) Belgium Volition Diagnostics UK Limited (100% subsidiary of Belgian Volition SRL) United Kingdom Volition Germany G |
|
| March 22, 2021 |
Certain confidential information contained in this document, marked by [***], has been omitted because it (i) is not material and would be competitively harmful if publicly disclosed, or (ii) contains personally identifiable information, omitted pursuant to Item 601(a)(6) under Regulation S-K. |
|
| March 22, 2021 |
Annual Report - FORM 10-K ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact |
|
| March 1, 2021 |
Schedule 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* VolitionRx Limited (Name of Company) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) Cameron Reynolds 13215 Bee Cave Parkway, Suite 125 Galleria Oaks B, Austin, TX 78738 +1 (646) 650-1351 |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* VolitionRx Limited (Name of Company) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) Guy Archibald Innes 13215 Bee Cave Parkway Suite 125 Galleria Oaks B, Austin, TX 78738 +1 (646) 650-1351 With a copy t |
|
| March 1, 2021 |
Schedule 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* VolitionRx Limited (Name of Company) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) Martin Charles Faulkes 13215 Bee Cave Parkway Suite 125 Galleria Oaks B, Austin, TX 78738 +1 (646) 650- |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VolitionRX Ltd (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 928661107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 12, 2021 |
Execution Version VOLITIONRX LIMITED 3,809,524 Shares of Common Stock (par value $0. |
|
| February 12, 2021 |
VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock AUSTIN, Texas, February 10, 2021 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (?Volition?), a multi-national epigenetics company that applies its Nucleosomics? platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced the pricing of its underwritten public offering of 3,809,524 shares of its common stock (the ?Offering?) for gross proceeds of approximately $20 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. |
|
| February 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2021 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission File Number) (IRS Em |
|
| February 11, 2021 |
4,380,952 Shares VOLITIONRX LIMITED Common Stock Form 424b5 Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| February 9, 2021 |
Subject to Completion, dated February 9, 2021 424b5 Preliminary Prospectus The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 9, 2021 |
Results of Operations and Financial Condition, Other Events - FORM 8-K CURRENT REPORT Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 2, 2021 |
VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts Exhibit 99.1 Press Release VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts AUSTIN, Texas, February 2, 2021 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today provided a business update and announced the appointment of a new Chief Financial Officer, Mr. Terig Hughes, in addition to the appointment of Dr. Gaetan Michel as Chi |
|
| February 2, 2021 |
Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 15, 2021 |
Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 3, 2020 |
Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 3, 2020 |
VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors EX-99.1 2 f8k120220ex99z1.htm EXHIBIT 99.1 PRESS RELEASE VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors AUSTIN, Texas, December 3, 2020 /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and an |
|
| November 12, 2020 |
Quarterly Report - FORM 10-Q QUARTERLY REPORT Form 10-Q Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 12, 2020 |
Form 8-K Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 12, 2020 |
Exhibit 10.1 Consulting Services Agreement Exhibit 10.1 CONSULTING SERVICES AGREEMENT THIS CONSULTING AGREEMENT (this “Agreement”), is entered into as of December 1, 2020 (the “Effective Date”) by and between Singapore Volition Pte. Limited, a Singapore corporation with its office located at 111 Somerset Road, Level 3, TripleOne Somerset, Singapore 238164 (the “Company”) and PB Commodities Pte. Lt |
|
| November 12, 2020 |
Up to $25,000,000 VOLITIONRX LIMITED Common Stock 424b5 Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Registration No. 333-227248 PROSPECTUS SUPPLEMENT (To Prospectus dated September 28, 2018) Up to $25,000,000 VOLITIONRX LIMITED Common Stock We have entered into an Equity Distribution Agreement, dated November 12, 2020, or the Distribution Agreement, with Cantor Fitzgerald & Co., or Cantor, and Oppenheimer & Co. Inc., or Oppenheimer, re |
|
| November 12, 2020 |
Exhibit 1.1 Equity Distribution Agreement Exhibit 1.1 VOLITIONRX LIMITED $25,000,000 COMMON STOCK EQUITY DISTRIBUTION AGREEMENT November 12, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, New York 10004 Ladies and Gentlemen: VolitionRx Limited, a Delaware corporation (the “Company”), confirms its agreement (this “Agreeme |
